Drug Interactions between Esbriet and prednisone
This report displays the potential drug interactions for the following 2 drugs:
- Esbriet (pirfenidone)
- prednisone
Interactions between your drugs
No interactions were found between Esbriet and prednisone. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Esbriet
A total of 129 drugs are known to interact with Esbriet.
- Esbriet is in the drug class miscellaneous uncategorized agents.
- Esbriet is used to treat Idiopathic Pulmonary Fibrosis.
prednisone
A total of 588 drugs are known to interact with prednisone.
- Prednisone is in the drug class glucocorticoids.
-
Prednisone is used to treat the following conditions:
- Acute Lymphocytic Leukemia
- Adrenocortical Insufficiency
- Adrenogenital Syndrome
- Allergic Reactions
- Allergic Rhinitis
- Allergies
- Amyloidosis
- Ankylosing Spondylitis
- Aspiration Pneumonia
- Asthma
- Atopic Dermatitis
- Autoimmune Hemolytic Anemia
- Berylliosis
- Bullous Pemphigoid
- Bursitis
- Chorioretinitis
- Cluster Headaches
- Cogan's Syndrome
- Conjunctivitis, Allergic
- COPD
- Corneal Ulcer
- Crohn's Disease, Active
- Dermatitis Herpetiformis
- Dermatomyositis
- Diffuse Large B-Cell Lymphoma
- Eczema
- Epicondylitis, Tennis Elbow
- Erythroblastopenia
- Fibromyalgia
- Food Allergies
- Giant Cell Arteritis
- Gouty Arthritis
- Graft-versus-host disease
- Herpes Zoster
- Herpes Zoster Iridocyclitis
- Hypercalcemia of Malignancy
- Immune Thrombocytopenia
- Immunosuppression
- Inflammatory Bowel Disease
- Inflammatory Conditions
- Interstitial Lung Disease
- Iridocyclitis
- Iritis
- Juvenile Rheumatoid Arthritis
- Keratitis
- Leukemia
- Lichen Planopilaris
- Lichen Planus
- Lichen Sclerosus
- Loeffler's Syndrome
- Lupus
- Lupus Nephritis
- Lymphoma
- Mixed Connective Tissue Disease
- Multiple Sclerosis
- Mycosis Fungoides
- Nephrotic Syndrome
- Neurosarcoidosis
- Optic Neuritis
- Osteoarthritis
- Pemphigoid
- Pemphigus
- Pharyngitis
- Polymyalgia Rheumatica
- Polymyositis/Dermatomyositis
- Psoriasis
- Psoriatic Arthritis
- Ramsay Hunt Syndrome
- Rheumatoid Arthritis
- Sarcoidosis
- Scleroderma
- Seborrheic Dermatitis
- Sinusitis
- Skin Rash
- Synovitis
- Systemic Sclerosis
- Thrombocytopenia
- Toxic Epidermal Necrolysis
- Tuberculosis, Extrapulmonary
- Tuberculous Meningitis
- Ulcerative Colitis, Active
- Uveitis, Posterior
Drug and food interactions
pirfenidone food
Applies to: Esbriet (pirfenidone)
ADJUST DOSING INTERVAL: Food significantly slows the rate but only modestly reduces the extent of absorption of pirfenidone. In healthy, older adult volunteers aged 50 to 66 years, administration of a single 801 mg oral dose of pirfenidone in the fed state resulted in an approximately 50% reduction in peak plasma concentration (Cmax) and a 15% to 20% reduction in systemic exposure (AUC) compared to administration in the fasted state. Median time to reach peak concentration (Tmax) increased from 0.5 hours to 3 hours with food. Less nausea and dizziness were observed in fed subjects compared to fasted subjects.
GENERALLY AVOID: Consumption of grapefruit juice is associated with inhibition of CYP450 1A2 and may increase the plasma concentrations of pirfenidone, which is primarily metabolized by the isoenzyme.
GENERALLY AVOID: Cigarette smoking may reduce pirfenidone exposure due to induction of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of pirfenidone. Following a single 801 mg oral dose of pirfenidone in 25 smokers and 25 healthy nonsmokers, the Cmax and AUC of pirfenidone in smokers were 68% and 46% of those in nonsmokers, respectively.
MANAGEMENT: Pirfenidone should be administered with food to reduce the likelihood of dizziness and gastrointestinal side effects such as nausea, diarrhea, dyspepsia, and vomiting. Patients who experience intolerance to therapy due to these adverse events should be reminded to take pirfenidone with food. If symptoms do not improve, or they worsen in severity, a dosage reduction or discontinuation of therapy may be warranted. Patients should be advised to avoid consumption of grapefruit and grapefruit juice during treatment with pirfenidone. Cigarette smoking should also be avoided during therapy to prevent reduced exposure to pirfenidone.
References
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2013) "Product Information. Esbriet (pirfenidone)." Intermune Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.